Clinical trials: Intravenous Infusions
Hepatitis B Infection
A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients
This is a proof-of-concept study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.
- Trial name
- NCT02304315
- Testing
- GC1102 50,000 IU, GC1102 80,000 IU
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Green Cross Corporation
Healthy Volunteers
A Pharmacokinetic Study of Intravenous NTM-001 in Healthy Chinese Subjects
This will be a single center, open-label phase 1 study in healthy Chinese subjects. A total of up to 16 subjects may be enrolled to achieve a total target of 12 evaluable subjects.
- Trial name
- NCT05382546
- Testing
- Ketorolac Tromethamine
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuance Pharma (shanghai) Co., Ltd
Ulcerative Colitis (UC), Crohn's Disease
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation…
- Trial name
- NCT04254783
- Testing
- Risankizumab, Cytochrome P450 (CYP) Substrates
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- AbbVie
Advanced Solid Tumors, Metastatic Solid Tumors
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors.
- Trial name
- NCT06770764
- Testing
- ODC-IL2
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Trutino Biosciences Inc.
β-thalassemia
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector…
- Trial name
- NCT06465550
- Testing
- BD211
- Where
- 3 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Alzheimer's Disease
A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of R1450 in patients with mild to moderate Alzheimer Disease.
- Trial name
- NCT00531804
- Testing
- gantenerumab
- Where
- 9 sites in Denmark, Israel and 3 more
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Malignancy
Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
An Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy (Hematologic or Nonhematologic)
- Trial name
- NCT00863850
- Testing
- bendamustine
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Cephalon
Recurrent Adult Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion, in patients with relapsed or refractory AML.
- Trial name
- ARMY (NCT02353143)
- Testing
- MEN1112
- Where
- 29 sites in Belgium, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Menarini Group
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis
The purpose of this study is to determine whether TZP-101 is safe in people with diabetes. Also to determine if TZP-101 is effective in increasing the gastric emptying rate in diabetic patients.
- Trial name
- NCT00639808
- Testing
- 5% dextrose in water, TZP-101
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 10 people
- Sponsor
- Tranzyme, Inc.
Neoplasms, Malignant
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors
Primary Objective: To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of ombrabulin in combination with cisplatin administered every 3 weeks in patients with…
- Trial name
- NCT01021150
- Testing
- ombrabulin (AVE8062), cisplatin
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Sanofi
Healthy
Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects
This is a randomized, placebo controlled, single dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-E2 in healthy male subjects.
- Trial name
- GX-E2-P1 (NCT02291991)
- Testing
- GX-E2
- Where
- South Korea
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Crohn's Disease
Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.
- Trial name
- NCT04002180
- Testing
- Vedolizumab (Genetical Recombination)
- Where
- Japan
- Volunteers
- 335 people
- Sponsor
- Takeda
Advanced Colorectal Cancer
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall…
- Trial name
- NCT00824161
- Testing
- TAS-109
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Heathly Subjects
Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects
1. Part 1 Randimization, Double blinded, Placebo controlled, Dose escalation(10mg, 20mg, 40mg) of MIT-001 SC or IV single administration to evaluate safety, tolerability and PK in healthy adult. 2.
- Trial name
- NCT05389696
- Testing
- Single subcutaneous administration and Blood collection, Single subcutaneous administration and then IV injection., MIT-001 20mg and 40mg_Multiple administration
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MitoImmune Therapeutics
Asthma, Healthy
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
- Trial name
- NCT00638989
- Testing
- CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal…
- Trial name
- NCT00503113
- Testing
- ibandronate [Bonviva/Boniva], Alendronate
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 801 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
The purpose of this study is to characterize the pharmacokinetic (PK) profile of pembrolizumab (MK-3475) following single subcutaneous (SC) injection of pembrolizumab Dose A versus pembrolizumab Dose C in adults with advanced…
- Trial name
- NCT03665597
- Testing
- Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B
- Where
- 15 sites in Australia, South Africa and 2 more
- Volunteers
- 138 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-hematological Malignancies
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.
- Trial name
- PK-CIA-04 (NCT01213979)
- Testing
- 500 mg iron isomaltoside 1000, 1000 mg iron isomaltoside 1000
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Healthy
Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers
This study will investigate the safety and tolerability of the first IV dosing of SLV338 in healthy volunteers.
- Trial name
- NCT00885989
- Testing
- SLV338
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Prostate Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic…
- Trial name
- NCT00024414
- Testing
- DHA-paclitaxel
- Where
- 8 sites in United States
- Sponsor
- Theradex